163 related articles for article (PubMed ID: 27569424)
41. G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis.
Moran BM; Flatt PR; McKillop AM
Acta Diabetol; 2016 Apr; 53(2):177-88. PubMed ID: 26739335
[TBL] [Abstract][Full Text] [Related]
42. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
Wang Y; Yu M; Zhu J; Zhang JK; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Liu JJ; Coward P
Bioorg Med Chem Lett; 2014 Feb; 24(4):1133-7. PubMed ID: 24440299
[TBL] [Abstract][Full Text] [Related]
43. The GABA
Olianas MC; Dedoni S; Onali P
Eur J Pharmacol; 2017 Jan; 794():135-146. PubMed ID: 27876620
[TBL] [Abstract][Full Text] [Related]
44. Activation and signaling mechanism revealed by GPR119-G
Qian Y; Wang J; Yang L; Liu Y; Wang L; Liu W; Lin Y; Yang H; Ma L; Ye S; Wu S; Qiao A
Nat Commun; 2022 Nov; 13(1):7033. PubMed ID: 36396650
[TBL] [Abstract][Full Text] [Related]
45. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
46. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus.
Manaithiya A; Alam O; Sharma V; Javed Naim M; Mittal S; Khan IA
Bioorg Chem; 2021 Aug; 113():104998. PubMed ID: 34048996
[TBL] [Abstract][Full Text] [Related]
47. Regulation of food intake by oleoylethanolamide.
Lo Verme J; Gaetani S; Fu J; Oveisi F; Burton K; Piomelli D
Cell Mol Life Sci; 2005 Mar; 62(6):708-16. PubMed ID: 15770421
[TBL] [Abstract][Full Text] [Related]
48. Discovery and Characterization of Biased Allosteric Agonists of the Chemokine Receptor CXCR3.
Milanos L; Brox R; Frank T; Poklukar G; Palmisano R; Waibel R; Einsiedel J; Dürr M; Ivanović-Burmazović I; Larsen O; Hjortø GM; Rosenkilde MM; Tschammer N
J Med Chem; 2016 Mar; 59(5):2222-43. PubMed ID: 26862767
[TBL] [Abstract][Full Text] [Related]
49. Noribogaine is a G-protein biased κ-opioid receptor agonist.
Maillet EL; Milon N; Heghinian MD; Fishback J; Schürer SC; Garamszegi N; Mash DC
Neuropharmacology; 2015 Dec; 99():675-88. PubMed ID: 26302653
[TBL] [Abstract][Full Text] [Related]
50. High constitutive signaling of the ghrelin receptor--identification of a potent inverse agonist.
Holst B; Cygankiewicz A; Jensen TH; Ankersen M; Schwartz TW
Mol Endocrinol; 2003 Nov; 17(11):2201-10. PubMed ID: 12907757
[TBL] [Abstract][Full Text] [Related]
51. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells.
Sakamoto Y; Inoue H; Kawakami S; Miyawaki K; Miyamoto T; Mizuta K; Itakura M
Biochem Biophys Res Commun; 2006 Dec; 351(2):474-80. PubMed ID: 17070774
[TBL] [Abstract][Full Text] [Related]
52. Discovery of pyrazolo[3,4-d]pyrimidine derivatives as GPR119 agonists.
Gillespie P; Goodnow RA; Saha G; Bose G; Moulik K; Zwingelstein C; Myers M; Conde-Knape K; Pietranico-Cole S; So SS
Bioorg Med Chem Lett; 2014 Feb; 24(3):949-53. PubMed ID: 24412066
[TBL] [Abstract][Full Text] [Related]
53. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
[TBL] [Abstract][Full Text] [Related]
54. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119.
Semple G; Fioravanti B; Pereira G; Calderon I; Uy J; Choi K; Xiong Y; Ren A; Morgan M; Dave V; Thomsen W; Unett DJ; Xing C; Bossie S; Carroll C; Chu ZL; Grottick AJ; Hauser EK; Leonard J; Jones RM
J Med Chem; 2008 Sep; 51(17):5172-5. PubMed ID: 18698756
[TBL] [Abstract][Full Text] [Related]
55. GPR119: a promising target for nonalcoholic fatty liver disease.
Yang JW; Kim HS; Im JH; Kim JW; Jun DW; Lim SC; Lee K; Choi JM; Kim SK; Kang KW
FASEB J; 2016 Jan; 30(1):324-35. PubMed ID: 26399788
[TBL] [Abstract][Full Text] [Related]
56. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
57. Structural Insight on GPR119 Agonist as Potential Therapy for Type II Diabetes: A Comprehensive Review.
Nema P; Asati V; Kendya P; Gupta T; Agarwal S; Kori S; Kashaw V; Iyer AK; Kashaw SK
Mini Rev Med Chem; 2023; 23(21):2008-2040. PubMed ID: 36861804
[TBL] [Abstract][Full Text] [Related]
58. Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice.
Al-Barazanji K; McNulty J; Binz J; Generaux C; Benson W; Young A; Chen L
J Pharmacol Exp Ther; 2015 Jun; 353(3):496-504. PubMed ID: 25770135
[TBL] [Abstract][Full Text] [Related]
59. GPR119 regulates genetic markers of fatty acid oxidation in cultured skeletal muscle myotubes.
Cornall LM; Mathai ML; Hryciw DH; Simcocks AC; O'Brien PE; Wentworth JM; McAinch AJ
Mol Cell Endocrinol; 2013 Jan; 365(1):108-18. PubMed ID: 23069642
[TBL] [Abstract][Full Text] [Related]
60. Pharmacological Characterization of Low Molecular Weight Biased Agonists at the Follicle Stimulating Hormone Receptor.
De Pascali F; Ayoub MA; Benevelli R; Sposini S; Lehoux J; Gallay N; Raynaud P; Landomiel F; Jean-Alphonse F; Gauthier C; Pellissier LP; Crépieux P; Poupon A; Inoue A; Joubert N; Viaud-Massuard MC; Casarini L; Simoni M; Hanyaloglu AC; Nataraja SG; Yu HN; Palmer SS; Yvinec R; Reiter E
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
